PF-Atlas › Clinical Trials › NCT01417156

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31

Nintedanib · Phase 2

Registry ID
NCT01417156
Phase
Phase 2
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Boehringer Ingelheim
Start
2011-09
Enrollment
20
Locations
4

About this trial

Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial of BIBF 1120 (1199.31). Secondary objectives are to assess effects on some efficacy criteria during long term treatment with BIBF 1120 on top of pirfenidone.

View NCT01417156 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT01417156 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.